MedTrace Logo

A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis

NCT04706741 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2024-02-12

No results posted yet for this study

Summary

This is a multicenter, phase 2 trial to explore the efficacy and safety of Izokibep (ABY-035) in treating disease activity in patients with non-Infectious Intermediate, Posterior, Pan-Uveitis with significant disease activity at BL despite treatment with stable doses of corticosteroids (≥7 to ≤40 mg/day oral prednisolon or equivalent).

Conditions

  • Uveitis

Interventions

DRUG

Izokibep

Izokibep is an Interleukin-17 Inhibitor that will be administered subcutaneously

DRUG

Prednisone/Prednisolone

Background Corticosteroid

Sponsors & Collaborators

  • ACELYRIN Inc.

    lead INDUSTRY

Principal Investigators

  • Donald Betah, MD · ACELYRIN Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-06
Primary Completion
2022-08-25
Completion
2022-11-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04706741 on ClinicalTrials.gov